The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizons
Frontiers in Pharmacology · 08.05.2026 · 17
DOI: 10.3389/fphar.2026.1820481 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.05.2026. Verfasst von Prasanna Srinivasan Ramalingam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The epithelial-mesenchymal transition (EMT) is a central plasticity program in cancer. It enables carcinoma cells to acquire migratory, invasive, immunomodulatory, and therapy-resistant phenotypes. As a result, EMT is a key driver of metastatic progression and poor prognosis. This overview summarizes recent mechanistic innovations across EMT-inducing transcription factors (SNAIL, SLUG, TWIST, ZEB) and their interactions with major signaling cascades, including TGF-β/SMAD, Wnt/β-catenin, Notch, PI3K/AKT/mTOR, and Hippo (YAP/TAZ). Together, these cascades integrate cues from the TME to sustain partial/hybrid EMT states and maintain cancer stemness. We present a review of epigenetic and post-transcriptional regulation of EMT (DNA methylation, histone regulation, and non-coding RNAs) and their role in reversible states transitions and drug tolerance. The translational section highlights advance in biomarker development and limitations of the static, single-timepoint assays in capturing EMT dynamics. We describe the possibilities of longitudinal, multimodal assessment, such as liquid biopsy, spatial profiling, and integrative multi-omics, for real-time monitoring of EMT states. Moreover, we explore the therapeutic opportunities involving epigenetic regulators, RNA-based interventions, EMT-immune crosstalk target, and selected natural products that modulate EMT circuits. Lastly, we propose a precision-oncology model that can consolidate the use of EMT-state stratification (epithelial-predominant, hybrid-mesenchymal, mesenchymal-predominant), adaptive monitoring, and rational combination therapies (with immunotherapy, ferroptosis inducers, and targeted agents) to overcome metastasis and resistance. Taken together, positioning EMT as a continuous, druggable spectrum, over binary switch, allows patient stratification using biomarkers and supports the development of next-generation interventions to reduce the risk of metastasis and enhance long-term clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India.
- Sharda School of Pharmacy, Sharda University, Greater Noida, India.
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
- School of Health Sciences and Technology, UPES, Energy Acres, Dehradun, India.
- College of Pharmacy, Graphic Era Hill University, Bhimtal, India.
- Centre for Promotion of Research, Graphic Era (Deemed to be) University, Dehradun, India.
Zitieren
APA
Ramalingam, P. S., Ilma, B., Hussain, M. S., Jakhmola, V., Fatima, R., Rana, A. J., Agrawal, M., Ashique, S., Mekala, J. R., & Arumugam, S. (2026). The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizons. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1820481
Vancouver
Ramalingam PS, Ilma B, Hussain MS, Jakhmola V, Fatima R, Rana AJ, et al. The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizons. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1820481
BibTeX
@article{Ramalingam2026,
author = {Ramalingam, Prasanna Srinivasan and Ilma, Baby and Hussain, Md Sadique and Jakhmola, Vikash and Fatima, Rabab and Rana, Amita Joshi and Agrawal, Mohit and Ashique, Sumel and Mekala, Janaki Ramaiah and Arumugam, Sivakumar},
title = {The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizons},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1820481}
}
EUVIMED